• Torben Rixecker, Vadim Lesan, Manfred Ahlgrimm, Lorenz Thurner, Moritz Bewarder, Niels Murawski, Konstantinos Christofyllakis, Sarah Altmeyer, Angelika Bick, Stephan Stilgenbauer, Joerg Thomas Bittenbring, and Dominic Kaddu-Mulindwa.
• Department of Hematology, Oncology, Clinical Immunology, Rheumatology, Saarland University Medical School, Homburg, Germany. torben.rixecker@uks.eu.
• Bone Marrow Transplant. 2021 Jan 1; 56 (1): 195-201.

AbstractPatients undergoing intensive chemotherapy are usually in need for central venous catheters (CVC). Due to contradictory study results, relation of insertion site and CVC-associated complication rate in these patients is not clear. We therefore retrospectively analyzed CVC-related data of all patients undergoing intensive chemotherapy with high risk of febrile neutropenia according to NCCN criteria, who received a CVC at our bone marrow transplantation unit between May 2016 and December 2019. In total, 210 patients received 281 CVC. CVC were placed via either the subclavian-vein (SCV, n = 58; 20%) or the internal-jugular-vein (IJV, n = 223; 80%). Median duration of CVC-lifetime and neutropenic days per CVC were comparable between the two groups (IJV vs SCV: 23 days vs 21 days (p = 0.16) and 12 days vs 11 days (p = 0.65)). Both, time to CVC removal due to local inflammation and time to central line-associated bloodstream infection was significantly shorter in patients with SCV catheters (p = 0.013 and p = 0.045). CVC placed in the IJV were associated with significantly less catheter-related infectious events compared with CVC placed in the SCV. This difference was consistent across different subgroups including 88 patients undergoing allogeneic stem cell transplantation.

9 keywords...

hide…